The European Commission has approved a new formulation of the Bayer drug Levitra® (vardenafil HCI). Levitra 10mg orodispersible tablets will be the first erectile dysfunction (ED) medication available in this novel and convenient formulation. In contrast to other drugs of the same class, Levitra 10mg orodispersible tablets can be taken discreetly and conveniently without water, dissolving on the tongue within seconds, and have a minty taste.
In Europe, the launch roll-out will start in November 2010. In the U.S., the medication was already approved in June 2010 and will be marketed by GlaxoSmithKline and Merck & Co., Inc. under the tradename STAXYN™.
“We believe men with ED will appreciate a medication that is convenient and easy to take,” said Dr. Flemming Oernskov, Head of the Women‘s Healthcare and General Medicine Business Unit at Bayer Schering Pharma. The overall efficacy and safety of vardenafil has been widely demonstrated in numerous clinical trials. For this registration, Levitra 10mg orodispersible tablets were tested in two multinational Phase III trials.